The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Image Case Report: Refractory, Acute, Cutaneous Lupus

Image Case Report: Refractory, Acute, Cutaneous Lupus

June 14, 2022 • By Samantha C. Shapiro, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A 25-year-old Mexican American woman with a five-year history of systemic lupus erythematosus (SLE) presents with refractory, acute cutaneous lupus erythematosus (ACLE) and subacute cutaneous lupus erythematosus (SCLE) affecting the scalp, face and hands. Her serologic phenotype is characterized by elevated anti-nuclear, anti-double-stranded deoxyribonucleic acid (dsDNA), anti-ribonucleoprotein (RNP), anti-Smith and anti-SS-A (Ro) antibodies and chronically low serum complement levels.

You Might Also Like
  • Dermatologist, Rheumatologist Discuss Refractory Cutaneous Lupus Case
  • Case Report: Refractory Calciphylaxis in Lupus
  • Rheumatology Case Report: Bullous Lesions in Patient with Lupus
Explore This Issue
June 2022

Her clinical phenotype is characterized by ACLE, SCLE with features of Rowell syndrome (i.e., erythema multiforme-like lesions), arthralgia, oral ulcers, leukopenia and thrombocytopenia. She had no internal organ manifestations of disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Her cutaneous disease was refractory to multiple medications. Systemic therapies included 400 mg of hydroxychloroquine by mouth daily, 25 mg of subcutaneous methotrexate weekly and 1,500 mg of mycophenolate mofetil by mouth twice daily. Adjunctive topical corticosteroids and topical calcineurin inhibitors were ineffective. She had required prednisone since diagnosis, with doses ranging from 5 mg to 60 mg by mouth daily. When the prednisone was tapered below 10 mg by mouth daily, cutaneous disease flared.

Clinical Findings

The physical exam was notable for active ACLE and SCLE lesions despite adherence to combination therapy with hydroxychloroquine, mycophenolate mofetil, methotrexate, prednisone 10 mg daily and topicals. A classic malar butterfly rash of the forehead, chin and malar cheeks, with relative sparing of the nasolabial folds, was present (see Figure 1). Significant involvement of the posterior scalp and ears was seen, with residual scarring alopecia (see Figure 2). A maculopapular, erythematous and scaling rash presented on the dorsal and palmar surfaces of bilateral hands (see Figures 3 & 4). These photographs were obtained at her most recent clinic visit.

Classic malar butterfly rash of the forehead, chin and malar cheeks. Note the relative sparing of the nasolabial folds.

Figures 1 & 2. Classic malar butterfly rash of the forehead, chin and malar cheeks. Note the relative sparing of the nasolabial folds.

Discussion

Cutaneous involvement in SLE is common and heterogeneous, with rashes ranging from mild to severe and refractory. A predilection for sun-exposed areas exists, and photosensitivity is common. First-line treatment for ACLE includes sun protection, smoking cessation, topical therapies and antimalarial agents (e.g., hydroxychloroquine, chloroquine and quinacrine). For many patients, this approach alone may result in dramatic improvement, with one recent meta-analysis demonstrating significant response in 91% of ACLE cases.1

However, some patients may have refractory cutaneous disease, requiring augmented immunosuppression. Methotrexate and mycophenolate mofetil are both reasonable second-line treatment options. Azathioprine may also be considered, but is generally less efficacious than the aforementioned treatments.2

Our patient tried and failed maximum doses of both methotrexate and myco­phenolate mofetil on a background of hydroxychloroquine, as well as a brief trial of combination methotrexate, mycophenolate mofetil and hydroxychloroquine with careful lab monitoring for toxicity.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

A maculopapular erythematous, violaceous, scaling rash is evident on the dorsal and palmar surfaces of both hands.

Figures 3 & 4 A maculopapular erythematous, violaceous, scaling rash is evident on the dorsal and palmar surfaces of both hands.

Refractory cutaneous lupus has limited effective treatment options.

Refractory cutaneous lupus has limited effective treatment options. Consensus on the best therapeutic approach after failure of second-line agents is limited by low levels of evidence. However, as rheuma­tology health professionals, we are challenged to find a way to improve quality of life and permit steroid-sparing for these patients. In an expert perspective published in Arthritis & Rheumatology in 2020, lenalidomide is recommended as a potential third-line agent for refractory cases.2 Studies of several other therapies at varying stages of development are underway.

More Info: See discussion with a dermatologist on this case here.


Samantha C. Shapiro, MD, is an academic rheumatologist and an affiliate faculty member of the Dell Medical School at the University of Texas at Austin. She received her training in internal medicine and rheumatology at Johns Hopkins University, Baltimore. She is also a member of the ACR Insurance Subcommittee.

References

  1. Chasset F, Bouaziz J-D, Costedoat-Chalumeau N, et al. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: A systematic review and meta-analysis. Br J Dermatol. 2017 Jul; 177(1):188–196.
  2. Borucki R, Werth VP. Expert perspective: An evidence‐based approach to refractory cutaneous lupus erythematosus. Arthritis Rheumatol. 2020 Nov;72(11):1777–1785.

Pages: 1 2 | Multi-Page

Filed Under: Conditions, SLE (Lupus) Tagged With: case report, cutaneous lupus erythematosus (CLE), diagnostic imaging, image case, image case report, SLE Resource CenterIssue: June 2022

You Might Also Like:
  • Dermatologist, Rheumatologist Discuss Refractory Cutaneous Lupus Case
  • Case Report: Refractory Calciphylaxis in Lupus
  • Rheumatology Case Report: Bullous Lesions in Patient with Lupus
  • Case Report: A Lupus Patient with Abdominal Pain

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)